Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Consensus Statement by the North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology

Summary

NAION and GLP1 agonists: small but possible increased risk, which remains low. Consensus statement by the North American Neuro-Ophthalmology Society and American Academy of Ophthalmology.

Abstract

Recent studies have reported a possible association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and non-arteritic anterior ischemic optic neuropathy (NAION). The North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology provide consensus expert opinion and clinical guidance about this association. Currently available evidence primarily includes retrospective observational studies, many of which rely on analysis of electronic health record and administrative claims data and are subject to limitations. Although many report a small possible increased risk of NAION in patients taking GLP-1 RAs such as semaglutide, some studies report no correlation, and the overall magnitude of the risk of NAION remains low. Shared decision-making between each patient and their care team is warranted to decide whether to start, continue, or discontinue GLP-1 RAs.